Assessment of the efficacy and safety of the phytopharmacon STW 5 versus metoclopramide in functional dyspepsia - A retrolective cohort study;Wirksamkeit und unbedenklichkeit des phytopharmakons STW 5 versus metoclopramid bei funktioneller dyspepsie unter praxisbedingungen - Eine retrolektive kohortenstudie

Zeitschrift fur Gastroenterologie

Volumn 45, Issue 10, 2007, Pages 1041-1048

  Raedsch, Richard ^a   Hanisch, J ^b   Bock, P ^b   Sibaev, A ^c   Vinson, B ^d   Gundermann, K J ^e  

^a ST JOSEFS HOSPITAL   (Germany)

^b IFAG   (Switzerland)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d Steigerwald Arzneimittelwerk GmbH   (Germany)

^e Abteilung für Klinische Pharmakologie   (Poland)

Author keywords

Functional dyspepsia; Gastrointestinal motility; Irritable bowel; Phytotherapy

Indexed keywords

METOCLOPRAMIDE; PLANT MEDICINAL PRODUCT; STW 5; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTIEMETICS; COHORT STUDIES; DYSPEPSIA; HUMANS; INTERNATIONALITY; METOCLOPRAMIDE; PLANT EXTRACTS; PREVALENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 36049047988     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-963357     Document Type: Article

References (53)

1. Malfertheiner P, Holtmann G, Peitz U et al. Leitlinien der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten zur Behandlung der Dyspepsie. Z Gastroenterol 2001; 39: 937-956
2. Talley NJ, Stangheitini V, Heading RC et al. Functional gastrointestinal disorders. Gut 1999; 45 (2): 37-42
3. Leew KJ, Kindt S, Tack J. Pathophysiology of functional dyspepsia. Best Pract Res Clin Gastroenterol 2004; 18: 707-716
4. Drossman DA, Li Z, Andruzzi E et al. U.S.householder survey of functional gastrointestinal disorders. Prevalence, sociodemography and health impact. Dig Dis Sci 1993; 38: 1569-1580
5. Talley NJ, Weaver AL, Zinsmeister AR. Impact of functional dyspepsia on quality of life. Dig Dis Sci 1995; 40: 584-589
6. Nyren O, Lindberg G, Lindstrom E et al. Economic costs of functional dyspepsia (see comments). Pharmacoeconomics 1992; 1: 312-324
7. Jones MP, Sharp LK, Crowell MD. Psyhcosocial correlates of symptoms in functional dyspepsia. Clin Gastroenterol Hepatol 2005; 3: 521-528
8. Haag S, Talley NJ, Holtmann G. Symptom pattern in functional dyspepsia and irritable bowel syndrome: relationship to disturbances in gastric emptying and response to a nutrient challenge in consulters and non-consulters. Gut 2004; 53: 1445-1451
9. Tack J, Bisschops R, Sarnelli G. Pathophysiology and treatment of functional dyspepsia. Gastroenterology 2004; 127: 1239-1255
10. Smith ML. Functional dyspepsia pathogenesis and therapeutic options - Implications for management. Dig Liver Dis 2005; 37: 547-558
11. Allescher HD, Bockenhoff A, Knapp G et al. Treatment of non-ulcer dyspepsia: a meta-analysis of placebo-controlled prospective studies. Scand J Gastroenterol 2001; 36: 934-941
12. Talley NJ. Update on the role of drug therapy in non-ulcer dyspepsia. Rev Gastroenterol Disord 2003; 3: 25-30
13. Talley NJ. Dyspepsia: management guidelines for the millennium. Gut 2002; 50 (Suppl4): 72-78
14. Veldhuyzen van Zanten SJ, Jones MJ, Verlinden M et al. Efficacy of cisapride and domperidone in functional (nonulcer) dyspepsia: a meta-analysis. Am J Gastroenterol 2001; 96: 689-696
15. Hohenester B, Rühl A, Kelber O et al. Herbal extracts have potent and region-specific effects on gastric motility. Neurogastroenterol Motil 2004; 16: 765-773
16. Schempp H, Toth A, Weiser D et al. Antioxidative properties of Iberis amara extracts in biochemical model reactions. Arzneim Forsch 2003; 53: 568-577
17. Schempp H, Hippeli S, Weiser D et al. Comparison of the inhibition of myeloperoxidase-catalyzed hypochlorite formation in vitro and in whole blood by different plant extracts contained in a phytopharmacon treating functional dyspepsia. Arzneim Forsch 2004; 54: 389-395
18. Liu CY, Müller MH, Glatzle J et al. The herbal preparation STW 5 (Iberogast() desensitizes intestinal afferents in the rat small intestine. Neurogastroenterol Motil 2004; 16: 759-764
19. Simmen U, Loechner C, Jaeggi R et al. Iberogast((STW 5) and components interact with intestinal muscarinic, 5-HT3 and 5-HT4 receptors. Acta Horticulturae, WOCMAP III - Medical and Aromatic Plants Conference. Leuven, Belgien: Int Soc Horticultural Science, 2005, im Druck
20. Heinle H, Pascht U, Kelber O et al. Untersuchungen zum Einfluss von STW 5 (Iberogast) und seinen Komponenten auf die Histamin-induzierte und spontane Kontraktilität des Meerschweinchen-Ileums in vitro. Z Gastroenterol 2004; 42: 814-815
21. Storr M, Sibaev V, Weiser D et al. Herbal extracts modulate amplitude and frequency of slow waves in circular smooth muscle of mouse small intestine. Digestion 2004; 70: 257-264
22. Khayyal MT, Schemann M, El-Ghazaly M et al. Effect of the phytomedicinal combination (STW 5) on gastric hyperacidity and motility. Clin Exp Pharmacol Physiol 2004; 31 (Suppl): A164
23. Sailer R, Pfister-Hotz G, Iten F et al. Eine moderne phytotherapeutische Arzneimittelkombination zur Behandlung funktioneller Erkrankungen des Magen-Darm-Traktes (funktionelle Dyspepsie, Reizdarm) - von der Pflanzenheilkunde zur "Evidence Based Phytotherapy" - Eine systematische Obersicht. Forsch Komplementärmed Klass Naturheilkd 2002; 9 (Suppl 1): 1-20
24. Buchen D. Wirkung einer fixen Kombination bei gesicherter Non-Ulcus-Dyspepsie (NUD). Z Phytother 1994; 15: 24-27
25. Goebell H, Holtmann G. Überprüfung der Wirksamkeit und therapeutischen Sicherheit von Iberogast® (STW 5) und Iberis amara (STW 6) bei Patienten mit funktioneller Dyspepsie. Forschungsbericht PFK CRIII-003-94 G 1994
26. Madisch A, Melderis H, Mayr G et al. Ein Phytotherapeutikum und seine modifizierte Rezeptur bei funktioneller Dyspepsie. Gastroenterol 2001; 39: 511-517
27. Arnim U, Peitz U, Schumacher M et al. STW 5, a phytopharmacon for patients with functional dyspepsia. Results of a multicentre, placebo-controlled double-blind study. Am J Gastroenterol 2007; 102: 1268-1275
28. Rösch W, Liebregts T, Gundermann KJ et al. Phytotherapy for functional dyspepsia: A review of the clinical evidence for the herbal preparation STW 5. Phytomedicine 2006; 13: 114-121
29. Gundermann KJ, Godehardt E, Ulbrich M. The efficacy of a combination herbal medicine in the treatment of functional dyspepsia. Meta-analysis of randomised double-blind studies on the basis of a valid gastrointestinal symptom profile. MMW-Fortschr Med 2004; 146: 71-76
30. Melzer J, Rösch W, Reichling J et al. Meta-analysis: phytotherapy of functional dyspepsia with STW 5 (Iberogast). Aliment Pharmacol Ther 2004; 20: 1279-1287
31. Nicolai K. Funktionelle Gastroenteropathien im therapeutischen Blindvergleich von Metoclopramid mit dem Phytopharmakon Iberogast. Gastro-Entero-Hepatologie 1984; 2: 1-12
32. Rösch W, Vinson B, Sassin I. A randomised clinical trial comparing the efficacy of a herbal preparation STW 5 with the prokinetic drug cisapride in patients with dysmotility type of functional dyspepsia. Z Gastroenterol 2002; 40: 401-408
33. Bellach BM. Leitlinien und Empfehlungen zur Sicherung von Guter Epidemiologischer Praxis (GEP). Bundesgesundheitsblatt 2000; 43: 468-475
34. Adam B, Liebregts T, Saadat-Gilani K et al. Validation of the Gastrointestinal Symptom Score (GIS) for the assessment of symptoms in patients with functional dyspepsia. Aliment Pharmacol Ther 2005; 22: 357-363
35. Directive 2001/83/EC of the European Parliament and of the Council of 6 November on the Community code relating to human medicinal products. Official J Europ Commun 2001; L 311: 67-128
36. Feinstein AR. Clinical Epidemiology. The Architecture of Clinical Research. Philadelphia: Saunders, 1985; 1st ed
37. Schneider B. Analysis of therapeutic efficacy in observational cohort studies. Cancer Chemother Pharmacol 2001; 47 (Suppl): S35-S37
38. Grimes DA, Schulz KF. Cohort studies: marching towards outcomes. Lancet 2002; 359: 341-345
39. Horwitz RI, Yu EC. Assessing the reliability of epidemiologic data obtained from medical records. J Chronic Dis 1984; 37: 825-831
40. Hlatky MA, Califf RM, Harrell Jr FE et al. Comparison of predictions based on observational data with the results of randomized controlled clinical trials of coronary artery bypass surgery. J Amer Coll Cardiol 1988; 11: 237-245
41. Horwitz RI, Viscoli CM, Clemens JD et al. Developing improved observational methods for evaluating therapeutic effectiveness. Am J Med 1990; 89: 630-638
42. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000; 342: 1878-1886
43. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000; 342: 1887-1892
44. Wittenborg A, Bock PR, Hanisch J et al. Vergleichende epidemiologische Studie bei Erkrankungen des rheumatischen Formenkreises am Beispiel der Therapie mit nichtsteroidalen Antiphlogistika versus einem oralen Enzymkombinationspräparat. Arzneim Forschg 2000; 50: 728-738
45. Sakalová A, Bock PR, Dedik L et al. Retrolective cohort study of an additive therapy with an oral enzyme preparation in patients with multiple myeloma. Cancer Chemother Pharmacol 2001; 47 (Suppl): S38-S44
46. Beuth J, Ost B, Pakdaman A et al. Impact of complementary oral enzyme application on the postoperative treatment results of breast cancer patients - results of an epidemiological multicentre retrolective cohort study. Cancer Chemother Pharmacol 2001; 47 (Suppl): S45-S54
47. Popiela T, Kulig J, Hanisch J et al. Influence of a complementary treatment with oral enzymes on patients with colorectal cancers - an epidemiological retrolective cohort study. Cancer Chemother Pharmacol 2001; 47 (Suppl): S55-S63
48. Schumacher K, Schneider B, Reich G et al. Postoperative komplementäre Therapie des primären Mammakarzinoms mit lektin-normiertem Mistelextrakt - eine epidemiologische, kontrollierte, multizentrische, retrolektive Kohortenstudie. Dtsch Z Onkol 2002; 34: 106-114
49. Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Statist Assoc 1984; 79: 516-524
50. D'Agostino Jr RB. Propensity score methods for bias reduction in the comparison of a treatment to non-randomized control group. Stat Med 1998; 17: 2265-2281
51. Perkins SM, Tu W, Underhill MG et al. The use of propensity scores in pharmacoepidemiologic research. Pharmacoepidemiol Drug Saf 2000; 9: 93-101
52. Rosenbaum PR. Observational Studies. New York-Berlin-Heidelberg: Springer, 2002; 2nd ed
53. Stanghellini V, Ghidini C, Maccarini MR et al. Fasting and postprandial gastrointestinal motility in ulcer and non-ulcer dyspepsia. Gut 1992; 33: 184-190